Erratum: Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began [0.03%]
乳腺癌靶向治疗的发展：精准医学的起源 ERRATUM
Jane Lowe Meisel,Vyshak Alva Venur,Michael Gnant et al.
Jane Lowe Meisel et al.
Urvashi Mitbander Joshi,Jasmin Hundal,Jonaphine R Mata et al.
Urvashi Mitbander Joshi et al.
Erratum: Global Oncology: Tackling Disparities and Promoting Innovations in Low- and Middle-Income Countries [0.03%]
全球肿瘤学：根除贫富差距和促进低收入和中等收入国家的创新（勘误）
Regina Barragan-Carrillo,Fredrick Chite Asirwa,Rodrigo Dienstmann et al.
Regina Barragan-Carrillo et al.
Early-Onset Colorectal Cancer: From Genetic Discovery to Clinical Innovation [0.03%]
早发性结直肠癌：从基因发现到临床创新
Anita Turk,Sebastián Mondaca,Bruno Nervi et al.
Anita Turk et al.
The rising incidence of early-onset colorectal cancer (EOCRC) presents a growing challenge to traditional approaches in screening, treatment, and survivorship. EOCRC is increasingly recognized as a biologically distinct entity, driven by co...
New Drugs, New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies [0.03%]
新型药物与新型毒副反应：乳腺癌新药和新兴疗法的副作用
Alexis LeVee,Alana Deutsh,Ethan S Lindgren et al.
Alexis LeVee et al.
With the rapid introduction of novel breast cancer therapies, recognizing and managing side effects is essential to maintain adherence and improve outcomes. As novel oral endocrine therapies and combination strategies including targeted age...
Melanoma 3.0T-Tech Innovations, New Targeted Therapies, and T-Cell Breakthroughs [0.03%]
黑色素瘤3.0T技术革新、新型靶向疗法及T细胞新突破
Donald P Lawrence,Susan Swetter,Meredith McKean
Donald P Lawrence
New technologies and innovations are changing the future of melanoma care. Teledermatology and skin screening mobile apps aided by artificial intelligence (AI) diagnostic support could assist in closing disparity gaps in melanoma early dete...
Synthesis and Educational Overview of the ASCO-Society of Integrative Oncology Guidelines: On the Path to Implementation [0.03%]
ASCO-整合肿瘤学学会指南的合成与教育概览：走向实施之路
Krisstina Gowin,Eugene R Ahn,Ana Maria Lopez
Krisstina Gowin
Cancer care is rapidly changing. Advances in treatments therapeutics, such as gene and immunotherapies, have revolutionized patient outcomes and given new hope to survivors and cosurvivors. Despite these advances, disease- and treatment-rel...
Icro Meattini,Ana Tecic Vuger,Carlotta Becherini et al.
Icro Meattini et al.
The excellent cure rates documented in clinical trials today constitute a very high bar for attempts to de-escalate therapy for early-stage breast cancer (EBC). Moreover, any therapy de-escalation must be made in the context of an optimal m...
After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast Cancer [0.03%]
CDK4/6抑制剂之后激素受体阳性转移性乳腺癌的治疗进展
Jimmitti Teysir,Maxwell R Lloyd,Samer Alkassis et al.
Jimmitti Teysir et al.
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor-positive metastatic breast cancer, offering demonstrable improvements in both progression-free survival and overall survival. H...
Global Oncology: Tackling Disparities and Promoting Innovations in Low- and Middle-Income Countries [0.03%]
全球肿瘤学：应对低收入和中等收入国家的差异并促进创新
Regina Barragan-Carillo,Fredrick Chite Asirwa,Rodrigo Dienstmann et al.
Regina Barragan-Carillo et al.
Global cancer incidence is projected to rise dramatically, with over 35 million new cases anticipated by 2050, disproportionately affecting low- and middle-income countries (LMICs) where up to 70% of cancer deaths are expected to occur. Thi...